GlassScriptPhysician profile
Stacy L Miller
NPI 1427419183
$7,064.12
in general payments reported to CMS, 2019-2025
30 companies · $946 in 2025
The $946 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,527 · 2022: $2,565 · 2023: $1,864 · 2024: $162 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431 · Travel and Lodging: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.72 |
| Travel and Lodging | $541.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,736.84 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,065.82 | 2021-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $925.93 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Medtronic, INC. | $721.13 | 2025 | Interstim |
| E.R. Squibb & Sons, L.L.C. | $355.66 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $255.52 | 2021-2023 | Injectafer |
| Qol Medical, LLC | $246.16 | 2021-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $234.95 | 2021-2023 | Ocaliva |
| Ardelyx, INC. | $179.50 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $161.41 | 2021-2022 | |
| Celgene Corporation | $154.15 | 2022-2023 | Zeposia |
| Evoke Pharma, INC. | $140.50 | 2021-2023 | Gimoti |
| Nestle Healthcare Nutrition INC. | $136.47 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $102.84 | 2021-2022 | |
| Janssen Biotech, INC. | $89.79 | 2022-2024 | Stelara, Remicade, Simponi Aria |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $81.36 | 2022-2024 | |
| Progenics Pharmaceuticals, INC. | $64.85 | 2024-2025 | |
| Pfizer INC. | $60.09 | 2024-2025 | |
| Lucid Diagnostics INC. | $55.33 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $54.01 | 2023-2025 | Rebyota, Adstiladrin |
| Endo USA, INC. | $43.16 | 2025 | Xiaflex |
| Braintree Laboratories, INC. | $40.26 | 2021-2023 | Sutab |
| Redhill Biopharma INC. | $35.40 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $24.29 | 2025 | |
| Sumitomo Pharma America, INC. | $20.02 | 2025 | Orgovyx |
| Pacira Pharmaceuticals Incorporated | $18.75 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.81 | 2023 | |
| Alnylam Pharmaceuticals INC. | $14.73 | 2021 | |
| Organon LLC | $14.65 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.